Re-purposing, environmentally damaging HFC cryogenic chillers to environmentally inert natural refrigerants, for process chilling in the post Covid-19 pharmaceutical industry.

在接下来的几个月里，英国制药公司和研究机构将需要开发抗病毒药物来帮助克服症状，并开发疫苗来预防和帮助对抗COVID-19病毒的破坏性影响。将需要新的制造技术，如连续加工，以及疫苗的安全低温储存。这些过程需要-50到-80°C的温度才能正常运行。目前，基于机械压缩机的低温制冷系统使用高成本\[£690/kg\]对环境有害的HFC制冷剂气体。根据英国-欧盟和联合国的气候变化政策，这些气体将在未来10年内逐步淘汰。Likido目前生产低碳，高温工业热泵，使用无毒，非？易燃，环境惰性，不含CFC/HFC的“天然工作液”。利用利基多在天然制冷剂技术方面的经验及其独特的两级压缩机设计，在接下来的3个月里，Likido计划快速跟踪制造一种新的冷冻机，这种冷冻机将使用不含氢氟碳化物的“天然制冷剂气体”，可以在-70°C下运行，全球变暖潜势\[GWP\]小于50Ṫhis。新的创新将确保在低温下安全生产和储存药物和疫苗，并保持英国政府对气候变化立法的承诺。

Over the next few months, UK pharmaceutical companies and institutes will need to develop anti-viral drugs to help overcome symptoms and vaccines to protect against and help combat the devastating effect of the COVID-19 virus.Novel manufacturing techniques such as continuous processing, together with the safe low-temperature storage of vaccines will be required. These processes require temperatures between -50 and -80°C to operate correctly.Currently, mechanical compressor-based low-temperature refrigeration systems use high cost \[£690/kg\] environmentally damaging HFC refrigerant gases. These gases under the UK-EU and UN climate change policies are legislated to be phased out over the next 10 years.Likido currently manufactures low carbon, high-temperature industrial heat pumps that use a non-toxic, non-?ammable, environmentally inert, CFC/HFC free "natural working ?uid". Using Likido's experience in natural refrigerant technology and its unique two-stage compressors design, Likido over the next 3 months plan to fast track the manufacturing of a new range Cryochillers which will use HFC free "natural refrigerant gases that can operate down to -70°C and have global warming potential \[GWP\] of less than 50\.This new innovation will ensure safe production and storage of medicines and vaccines at low temperatures and keep the UK's government commitment to climate change legislation.